Holen Sie sich die Stockscreener-App
0.7349
6.16%
-0.0553
Schlusskurs vom Vortag:
$0.7902
Offen:
$0.7881
24-Stunden-Volumen:
6.48M
Relative Volume:
6.37
Marktkapitalisierung:
$2.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.47M
KGV:
-0.0189
EPS:
-38.9215
Netto-Cashflow:
$-8.38M
1W Leistung:
+5.16%
1M Leistung:
-35.52%
6M Leistung:
-78.13%
1J Leistung:
-97.53%
1-Tages-Spanne:
$0.6902
$0.7999
1-Wochen-Bereich:
$0.6902
$0.91
52-Wochen-Spanne:
$0.6902
$31.65
Artelo Biosciences Inc Stock (ARTL) Company Profile
Firmenname
Artelo Biosciences Inc
Sektor
Branche
Telefon
858-925-7049
Adresse
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
0.7448 | 2.75M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
515.47 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.53 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.02 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.46 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Eingeleitet | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus
Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire
Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan
Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com
Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade
Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results - Yahoo Finance
Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan
Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget
Artelo doses first patient in glaucoma study for ART27.13 - Investing.com
Artelo Biosciences, Inc. Enrolls First Patient in Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma - marketscreener.com
Price to book forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
Price to sales forward of Artelo Biosciences, Inc. – NASDAQ:ARTL - TradingView
ARTL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Artelo Biosciences (ARTL) Rises 1.96% as Shares Hold Between Key Support and ResistanceIchimoku Entry - dars.gov.et
Artelo Biosciences, Inc. Revenue Breakdown – NASDAQ:ARTL - TradingView
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences (ARTL) Edges Higher Near Resistance: Key Levels to WatchALMA Signal - dars.gov.et
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - marketscreener.com
New Analysis of Over 50 Studies Showed that All the - GlobeNewswire
Review of 50+ CBD studies finds drug interactions in retail products - Stock Titan
Form 4 Artelo Biosciences Inc For: 21 July By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director - Stock Titan
Artelo Biosciences (ARTL) grants small stock option award to director - Stock Titan
Artelo Biosciences (ARTL) awards 136-share stock option grant - Stock Titan
Artelo Biosciences grants options to director | ARTL Insider Trading - Stock Titan
ARTL Q4 2025 Earnings: Significant EPS Surprise Despite No RevenueEarnings Sentiment Score - dars.gov.et
Artelo Biosciences Q4 2025 Earnings: EPS Surprises Significantly vs. EstimatesRetail Earnings Report - dars.gov.et
Artelo Biosciences (ARTL) Proxy filing Summary - Quartr
Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies - Stock Titan
Artelo Biosciences (ARTL) AGM 2026 Summary - Quartr
ARTL: All proposals, including director elections and share increases, were approved - TradingView
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo presents preclinical data on osteoarthritis pain drug - Investing.com UK
Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P - GuruFocus
Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions - marketscreener.com
Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen - Quiver Quantitative
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - The Manila Times
These stocks are moving in today's after hours session - ChartMill
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 - The Manila Times
Every Artelo proxy helps reach quorum for July 17 meeting - Stock Titan
Artelo Biosciences reminds shareholders to vote before July 17 meeting - scanx.trade
Artelo reports positive neuropathic pain study results for ART27.13 - Investing.com UK
Artelo reports ART27.13 pain study results - grafa.com
Artelo Biosciences (ARTL) Reports Positive Findings on Pain Trea - GuruFocus
Artelo reports positive neuropathic pain study results for ART27.13 By Investing.com - Investing.com India
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy - The Manila Times
Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients - Quiver Quantitative
Finanzdaten der Artelo Biosciences Inc-Aktie (ARTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):